Pharmings PI3K-delta inhibitor, Joenja, wins first FDA nod in APDS - BioWorld Online
| PHARM Stock | EUR 0.83 0.02 2.35% |
About 62% of Pharming Group's investor base is looking to short. The analysis of current outlook of investing in Pharming Group NV suggests that many traders are alarmed regarding Pharming Group's prospects. The current market sentiment, together with Pharming Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets.
Pharming |
Pharmings PI3K-delta inhibitor, Joenja, wins first FDA nod in APDS BioWorld Online
Read at news.google.com
 |
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Pharming Group is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
| BAMNB | Koninklijke BAM | 5.01 | ||||
| GLPG | Galapagos | 0.78 | ||||
| PNL | PostNL NV | 1.94 | ||||
| FUR | Fugro NV | 2.24 | ||||
| AMG | AMG Advanced | 3.42 |
Complementary Tools for Pharming Stock analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |